[pending] ARIPIPRAZOLE (ARIPIPRAZOLE)
Pending LLM rewrite. Source: FDA_DRUG D-0594-2026.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Pending LLM scoring against the rubric.
Plain-English summary
Product Mix-Up: A bottle containing Voriconazole Tablets 50 mg was labelled and distributed as Aripiprazole Tablets USP 30 mg.
The recalled product
- Product
- ARIPIPRAZOLE (ARIPIPRAZOLE)
- Brand
- ARIPIPRAZOLE
- Manufacturer
- Ajanta Pharma USA Inc
- Category
- Drug — Drugs
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot: PA00805
- expires: 01/31/2029
UPCs (6)
- 0327241051036
- 0327241055034
- 0327241053030
- 0327241056031
- 0327241054037
- 0327241052033
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · ARIPIPRAZOLE
- ModeratePrescription Aripiprazole tablets recalled nationwide for storage temperature deviation
FDA (Drugs) · 2024-01-03
- HighAntipsychotic Drug Recalled for Failed Quality Control Test
FDA (Drugs) · 2023-04-26
- HighAccord Healthcare Recalls Aripiprazole Tablets Due to Manufacturing Deviations
FDA (Drugs) · 2023-03-08
- ModerateAripiprazole 15 mg Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2023-03-08
- HighAripiprazole 20 mg Tablets Recalled for Manufacturing Quality Deviations
FDA (Drugs) · 2023-03-08
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateMedline Ophthalmic Pack with Lidocaine Injection Kits Recalled
FDA (Devices) · 2026-07-08
- SevereAccucaine Lidocaine Injection Recalled for Lack of Sterility Assurance
FDA (Drugs) · 2026-07-08
- SevereChloraPrep One-Step Sterile Solution Lacks Assurance of Sterility
FDA (Drugs) · 2026-07-08
- SevereChloraPrep One-Step Antiseptic Applicators recalled for lack of sterility assurance
FDA (Drugs) · 2026-07-08